Steven Gannon, a director of Xenon Pharmaceuticals Inc., filed a statement of changes in beneficial ownership on August 13, 2026, reporting the sale of 10,000 common shares on August 11, 2026.
Key Highlights
- Shares sold: Steven Gannon disposed of 10,000 common shares of Xenon Pharmaceuticals Inc. on August 11, 2026.
- Weighted-average price: The shares were sold at a weighted-average price of $64.055, with individual transaction prices ranging from $64.0517 to $64.078, inclusive, according to the filing.
- Remaining ownership: Following the transaction, Gannon directly holds 1,870 common shares, as reported in the filing.
- Role of reporting person: Gannon is identified in the filing as a director of Xenon Pharmaceuticals Inc., listed on NASDAQ:XENE.
- Multiple transactions: The filing discloses that the reported amount and price reflect an aggregate of shares sold across multiple transactions within the stated price range.
Director Share Sale Details at Xenon Pharmaceuticals
According to the filing, Steven Gannon, whose address is listed as 3650 Gilmore Way, Burnaby, British Columbia, Canada, sold 10,000 common shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) on August 11, 2026. The transaction was coded "S," indicating an open-market sale. The filing was signed by Nathaniel Adams as attorney-in-fact and submitted on August 13, 2026.
The filing notes that the reported price of $64.055 is a weighted-average across multiple transactions, with individual sales occurring at prices ranging from $64.0517 to $64.078, inclusive. The filing states that Gannon "undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein." No derivative securities transactions were reported in Table II of the filing.
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company. After the reported sale, Gannon's direct beneficial ownership in the company stands at 1,870 common shares, as disclosed in the filing. No indirect ownership is reported. The filing was made by one reporting person and is not an amendment to a prior filing.
What Was Disclosed
The filing discloses a sale of 10,000 Xenon Pharmaceuticals common shares by director Steven Gannon on August 11, 2026, at a weighted-average price of $64.055, leaving him with direct beneficial ownership of 1,870 shares.




Please wait processing your request...